NPM1 mutation was found in 31 patients (6%, 24 of them had t‐AML and 7 had MRC‐AML with a documented previous history of MDS); all patients with NPM1 mutations fulfilled criteria for CPX treatment (e.g., a history of MDS or additional molecular or cytogenetic changes characteristic of s‐AML). Here, NPM1 is linked to myelodysplastic syndrome.